FibroGen Inc (OQ:FGEN)

Business Focus: Biotechnology & Medical Research

Apr 24, 2024 04:02 pm ET
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Prese
FibroGen, Inc. (NASDAQ: FGEN) today announced that clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer have been...
Apr 02, 2024 05:46 pm ET
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
FibroGen, Inc. (NASDAQ: FGEN) today announced topline data from the Fortis Therapeutics-sponsored Phase 1 study of FG-3246 (also known as FOR46), a potential first-in-class anti-CD46 antibody drug conjugate (ADC) with an MMAE-containing payload, in...
Mar 26, 2024 07:00 am ET
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a corporate presentation at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, from 3:00-3:40 PM Eastern...
Mar 11, 2024 07:00 am ET
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical...
Feb 26, 2024 04:06 pm ET
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year 2023 and provided an update on the company’s recent developments. “We are extremely excited about the company’s prospects in 2024,” said Thane...
Feb 26, 2024 04:05 pm ET
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea
FibroGen, Inc. (NASDAQ: FGEN) announced today that FibroGen and AstraZeneca have agreed to terminate the U.S./RoW roxadustat collaboration agreement entered into on July 30, 2013, under which AstraZeneca held development and commercialization...
Feb 20, 2024 07:00 am ET
FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2023 financial results on Monday, February 26 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment...
Feb 05, 2024 07:00 am ET
FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024
FibroGen, Inc. (NASDAQ: FGEN) today announced it will host Part I of a virtual KOL investor event series on Tuesday, February 13, 2024 at 10:30 AM ET. To register, click here. The event will feature Andrew Ko, MD (University of California...
Jan 25, 2024 07:00 am ET
FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer
FibroGen, Inc. (NASDAQ: FGEN) announced graduation and completion of the pamrevlumab experimental arm in the Pancreatic Cancer Action Network's (PanCAN) Precision PromiseSM Phase 2/3 adaptive platform trial, which evaluates pamrevlumab in...
Dec 26, 2023 09:00 pm ET
FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against FibroGen, Inc. (NASDAQ: FGEN) on behalf of long-term stockholders following a class action complaint that was filed against FibroGen on April 12, 2021 with a Class Period from December 20, 2018 to July 15, 2021. Our investigation concerns whether the board of directors of FibroGen have breached their fiduciary duties to the company.
Dec 09, 2023 05:02 pm ET
FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meetin
FibroGen, Inc. (NASDAQ: FGEN) announced today the presentation of efficacy and safety data from MATTERHORN, a Phase 3 clinical study of roxadustat for the treatment of anemia in patients with lower risk transfusion-dependent myelodysplastic...
Nov 06, 2023 04:01 pm ET
FibroGen Reports Third Quarter 2023 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter 2023 and provided an update on the Company’s recent developments. “Today, we reported another quarter of strong roxadustat volume growth in China,...
Oct 23, 2023 07:00 am ET
FibroGen to Report Third Quarter 2023 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2023 financial results on Monday, November 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to...
Oct 06, 2023 03:00 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / October 6, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ:FGEN) for violations of the securities laws.
Sep 27, 2023 01:00 pm ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ:FGEN) for violations of the securities laws.
Sep 25, 2023 12:30 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / September 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ:FGEN) for violations of the securities laws.
Aug 29, 2023 04:15 pm ET
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
FibroGen, Inc. (NASDAQ: FGEN) today announced topline data from the Phase 3 LELANTOS-2 trial of pamrevlumab for the treatment of ambulatory patients with Duchenne muscular dystrophy (DMD) on background systemic corticosteroids. The study did not...
Aug 29, 2023 05:00 am ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ:FGEN) for violations of the securities laws.
Aug 25, 2023 05:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ:FGEN) for violations of the securities laws.
Aug 07, 2023 04:01 pm ET
FibroGen Reports Second Quarter 2023 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the second quarter 2023 and provided an update on the Company’s recent developments. “We saw another record quarter of roxadustat sales in China, and we recently submitted the sNDA...
Aug 04, 2023 05:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 4, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ:FGEN) for violations of the securities laws.
Jul 31, 2023 06:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 31, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ:FGEN) for violations of the securities laws.
Jul 25, 2023 07:00 am ET
FibroGen Announces Leadership Transition
FibroGen, Inc. (NASDAQ: FGEN), today announced the appointment of Thane Wettig as the Company’s interim Chief Executive Officer effective as of July 23, 2023. Mr. Wettig has served as FibroGen’s Chief Commercial Officer and a key member of the...
Jul 25, 2023 06:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ:FGEN) for violations of the securities laws.
Jul 24, 2023 07:00 am ET
FibroGen to Report Second Quarter 2023 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2023 financial results on Monday, August 7 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to...
Jul 21, 2023 06:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ:FGEN) for violations of the securities laws.
Jul 19, 2023 02:24 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN
Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980. The...
Jul 19, 2023 06:00 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ:FGEN) for violations of the securities laws.
Jul 17, 2023 05:38 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN
NEW YORK, July 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jul 17, 2023 06:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ:FGEN) for violations of the securities laws.
Jul 13, 2023 07:00 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 13, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ:FGEN) for violations of the securities laws.
Jul 12, 2023 01:07 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN
NEW YORK , July 12, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jul 11, 2023 07:00 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 11, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ:FGEN) for violations of the securities laws.
Jul 09, 2023 03:32 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN
Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Jul 08, 2023 07:00 am ET
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ: FGEN) for violations of the securities laws.
Jul 06, 2023 06:00 am ET
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 6, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ:FGEN) for violations of the securities laws.
Jul 04, 2023 12:05 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 4, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ:FGEN) for violations of the securities laws.
Jul 03, 2023 03:15 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN
NEW YORK, July 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Jul 03, 2023 01:00 am ET
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / July 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ:FGEN) for violations of the securities laws.
Jul 01, 2023 06:59 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN
Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN).   Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980. The...
Jun 30, 2023 10:46 pm ET
FIBROGEN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues its Investigation of the Officers and Directors of FibroGen, Inc. - FGEN
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into FibroGen, Inc. (NasdaqGS: FGEN). On July 15, 2021, the U.S. Food and...
Jun 30, 2023 12:45 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / June 30, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ:FGEN) for violations of the securities laws.
Jun 27, 2023 09:00 am ET
INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Fibrogen, Inc. and Encourages Investors With Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. (“FibroGen” or “the Company”) (NASDAQ:
Jun 26, 2023 12:54 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. (“FibroGen” or “the Company”) (NASDAQ:
Jun 26, 2023 09:31 am ET
Thinking about buying stock in Overstock.com, Trxade Health, FibroGen, SAI.TECH, or FingerMotion?
NEW YORK, June 26, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OSTK, MEDS, FGEN, SAI, and FNGR.
Jun 26, 2023 07:04 am ET
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
FibroGen, Inc. (NASDAQ: FGEN) today announced topline results from its Phase 3 ZEPHYRUS-1 trial evaluating the safety and efficacy of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF). The study compared treatment with pamrevlumab to...
Jun 16, 2023 10:50 pm ET
FIBROGEN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues its Investigation of the Officers and Directors of FibroGen, Inc. - FGEN
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into FibroGen, Inc. (NasdaqGS: FGEN). On July 15, 2021, the U.S. Food...
Jun 07, 2023 06:55 am ET
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
FibroGen, Inc. (NASDAQ: FGEN) today announced topline data from the Phase 3 LELANTOS-1 placebo-controlled trial of pamrevlumab for the treatment of non-ambulatory patients with Duchenne Muscular Dystrophy (DMD) on background corticosteroids. The...
Jun 06, 2023 04:01 pm ET
FibroGen to Present at Jefferies Global Healthcare Conference
FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following investor conferences: Jefferies Global Healthcare Conference taking place in New York, NY on...
Jun 06, 2023 01:22 pm ET
FIBROGEN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues its Investigation of the Officers and Directors of FibroGen, Inc. - FGEN
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into FibroGen, Inc. (NasdaqGS: FGEN). On July 15, 2021, the U.S. Food...
May 18, 2023 07:30 am ET
FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
FibroGen, Inc. (NASDAQ: FGEN) and its subsidiary, FibroGen (China) Medical Technology Development Co., Ltd. today announced positive topline data from Company’s Phase 3 clinical study of roxadustat for treatment of anemia in patients receiving...
May 08, 2023 04:01 pm ET
FibroGen Reports First Quarter 2023 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2023 and provided an update on the company’s recent developments. “We look forward to reporting topline data from four pivotal phase 3 trials through the...
May 08, 2023 04:00 pm ET
FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics
FibroGen, Inc. (Nasdaq: FGEN) and Fortis Therapeutics announced that FibroGen has entered into an exclusive license with Fortis Therapeutics for FOR46, a potential first-in-class Phase 1 antibody-drug conjugate (ADC) targeting a novel epitope on...
May 05, 2023 07:30 am ET
FibroGen Announces Results for MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)
FibroGen, Inc. (NASDAQ: FGEN) today announced that MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with transfusion-dependent lower risk myelodysplastic syndromes (MDS) did not meet its primary efficacy...
May 01, 2023 07:00 am ET
FibroGen Announces Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value
FibroGen, Inc. (NASDAQ: FGEN) today announced a non-dilutive term loan facility with investment funds managed by Morgan Stanley Tactical Value (MSTV) that will result in proceeds to FibroGen of up to $150 million, bringing significant non-dilutive...
Apr 24, 2023 07:00 am ET
FibroGen to Report First Quarter 2023 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2023 financial results on Monday, May 8 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further...
Apr 03, 2023 07:00 am ET
FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
FibroGen, Inc. (NASDAQ: FGEN) today announced the completion of patient enrollment for ZEPHYRUS-2, a Phase 3 clinical study of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF), a chronic, progressive, and fatal lung disease. “We...
Feb 27, 2023 04:01 pm ET
FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year 2022 and provided an update on the company’s recent developments. “We are proud of the significant progress advancing our clinical pipeline in 2022...
Feb 27, 2023 07:00 am ET
FibroGen to Present at Cowen’s 43rd Annual Health Care Conference
FibroGen, Inc. (NASDAQ: FGEN) today announced that Mark Eisner, M.D., M.P.H., Chief Medical Officer, will participate in a panel discussion at Cowen’s 43rd Annual Health Care Conference to be held in Boston on March 5 - 8, 2023. Details of the...
Feb 17, 2023 07:00 am ET
FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2022 financial results on Monday, February 27 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment...
Feb 02, 2023 07:00 am ET
FibroGen to Present at SVB Securities Global Biopharma Conference
FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Thursday, February 16 at 3:40 PM Eastern Time. The...
Jan 12, 2023 09:55 am ET
Thinking about buying stock in BigBear.ai, American Airlines, Akerna, Coinbase Global, or FibroGen?
NEW YORK, Jan. 12, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BBAI, AAL, KERN, COIN, and FGEN.
Jan 06, 2023 09:56 am ET
Thinking about buying stock in Mullen Automotive, FibroGen, Bed Bath & Beyond, DCP Midstream, or Li Auto?
NEW YORK, Jan. 6, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MULN, FGEN, BBBY, DCP, and LI.
Nov 28, 2022 07:00 am ET
FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual Conference
FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Bank of America 2022 Biotech SMID Cap Virtual Conference on December 8, at 1:05 PM Eastern Time. A live audio...
Nov 07, 2022 04:01 pm ET
FibroGen Reports Third Quarter 2022 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter 2022 and provided an update on the company’s recent developments. “I am very pleased with our progress across our clinical development programs with 3 pivotal...
Nov 07, 2022 04:00 pm ET
FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management
FibroGen, Inc. (NASDAQ: FGEN) today announced a royalty monetization financing with NovaQuest Capital Management (NovaQuest) that will result in proceeds to FibroGen in the amount of $50 million, bringing non-dilutive capital to drive innovation...
Nov 01, 2022 07:00 am ET
FibroGen to Participate at Stifel 2022 Healthcare Conference
FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Stifel 2022 Healthcare Conference in New York, NY taking place on November 15, at 1:50 PM Eastern Time. A...
Oct 24, 2022 07:00 am ET
FibroGen to Report Third Quarter 2022 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2022 financial results on Monday, November 7 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community...
Oct 14, 2022 09:41 am ET
Thinking about buying stock in Reviva Pharmaceuticals, Charge Enterprises, Applied DNA Sciences, Delta Air Lines, or FibroGen?
NEW YORK, Oct. 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RVPH, CRGE, APDN, DAL, and FGEN.
Aug 26, 2022 07:00 am ET
FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic
FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient enrollment for MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with lower risk transfusion-dependent myelodysplastic syndromes (MDS). “We...
Aug 19, 2022 10:50 pm ET
FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Provides Update of its Investigation of the Officers and Directors of FibroGen, Inc. - FGEN
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), provides an update to KSF’s continued investigation into FibroGen, Inc. (NasdaqGS: FGEN).
Aug 08, 2022 04:01 pm ET
FibroGen Reports Second Quarter 2022 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the second quarter 2022 and provided an update on the company’s recent developments. “We continue making excellent progress with pamrevlumab across all our high value indications...
Aug 05, 2022 10:50 pm ET
FIBROGEN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Provides Update of its Investigation of the Officers and Directors of FibroGen, Inc. - FGEN
NEW ORLEANS, Aug. 5, 2022 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), provides an update to KSF's continued investigation into FibroGen, Inc. (NasdaqGS: FGEN).
Jul 25, 2022 07:00 am ET
FibroGen to Report Second Quarter 2022 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2022 financial results on Monday, August 8 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community...
Jul 22, 2022 10:50 pm ET
FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Provides Update of its Investigation of the Officers and Directors of FibroGen, Inc. - FGEN
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), provides an update to KSF’s continued investigation into FibroGen, Inc. (NasdaqGS: FGEN).
Jul 19, 2022 01:33 pm ET
FibroGen Shareholder Alert: Shareholder Class Action Survives in Part Motion to Dismiss; Should Management be Held Accountable for Shareholder Losses? Contact Johnson Fistel, Globally-Recognized Law F
Johnson Fistel, LLP is investigating potential claims on behalf of FibroGen, Inc. (NASDAQ: FGEN) against certain of its officers and directors. If you are a current, long-term shareholder of FibroGen shares you may have standing to hold FibroGen...
Jul 01, 2022 07:00 am ET
FibroGen to Participate at William Blair Biotech Focus Conference 2022
FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the William Blair Biotech Focus Conference 2022 taking place the week of July 11, 2022. A webcast of the event...
Jun 08, 2022 07:00 am ET
FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy
FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient enrollment for LELANTOS-2, a Phase 3 clinical study of pamrevlumab in patients with ambulatory Duchenne muscular dystrophy (DMD). “We are very pleased to complete enrollment...
May 27, 2022 10:50 pm ET
FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of FibroGen, Inc. - FGEN
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into FibroGen, Inc. (NasdaqGS: FGEN).
May 26, 2022 07:00 am ET
FibroGen to Present at Jefferies Healthcare Conference
FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9 at 1:30pm EDT. A live audio webcast of the event will be...
May 13, 2022 10:50 pm ET
FIBROGEN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of FibroGen, Inc. - FGEN
NEW ORLEANS, May 13, 2022 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into FibroGen, Inc. (NasdaqGS: FGEN).
May 09, 2022 04:01 pm ET
FibroGen Reports First Quarter 2022 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2022 and provided an update on the company’s recent developments. “We continue our progress in advancing pamrevlumab in three high value indications and are...
May 05, 2022 03:17 pm ET
FIBROGEN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of FibroGen, Inc. - FGEN
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into FibroGen, Inc. (NasdaqGS: FGEN).
Apr 29, 2022 10:50 pm ET
FIBROGEN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of FibroGen, Inc. - FGEN
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into FibroGen, Inc. (NasdaqGS: FGEN).
Apr 25, 2022 07:00 am ET
FibroGen to Report First Quarter 2022 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2022 financial results on Monday, May 9 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to...
Apr 20, 2022 07:00 am ET
FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient enrollment for ZEPHYRUS-1, the first of two Phase 3 clinical studies of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF), a chronic, progressive, and fatal lung...
Feb 28, 2022 04:01 pm ET
FibroGen Reports Fourth Quarter and Full Year 2021 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year 2021 and provided an update on the company’s recent developments. “We are excited to advance pamrevlumab in three high value indications -...
Feb 14, 2022 07:00 am ET
FibroGen to Report Fourth Quarter and Full Year 2021 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2021 financial results on Monday, February 28 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the...
Feb 04, 2022 07:00 am ET
FibroGen to Present at SVB Leerink 11th Annual Global Healthcare Conference
FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Friday, February 18, 2022 at 3:40pm EST. The audio...
Jan 04, 2022 07:00 am ET
FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference
FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect Virtual Conference taking place January 10-13. The on-demand webcast of the session...
Dec 20, 2021 08:00 am ET
FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program
FibroGen, Inc. (Nasdaq: FGEN), a leading biopharmaceutical company discovering, developing, and commercializing first-in-class therapeutics, and HiFiBiO Therapeutics, a private, multinational clinical-stage biotherapeutics company with expertise in...
Dec 15, 2021 09:00 pm ET
FIBROGEN ALERT: Bragar Eagel & Squire, P.C. Is Investigating Fibrogen, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fibrogen, Inc. (NASDAQ: FGEN) on behalf of long-term stockholders following a class action complaint that was filed against Fibrogen on April 12, 2021. Our investigation concerns whether the board of directors of Fibrogen have breached their fiduciary duties to the company.
Nov 10, 2021 08:31 am ET
Thinking about buying stock in RenovoRx, Roblox, Fubotv, Unity Biotechnology, or FibroGen?
NEW YORK, Nov. 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for RNXT, RBLX, FUBO, UBX, and FGEN.
Nov 09, 2021 04:01 pm ET
FibroGen Reports Third Quarter 2021 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter 2021 and provided an update on the Company’s recent developments. “We and our partner Astellas are excited to be making Evrenzo available to patients in Europe,”...
Nov 02, 2021 07:00 am ET
FibroGen to Present at Upcoming Investor Conferences
FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the following healthcare conferences: Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16 at 4:40 PM...
Oct 26, 2021 07:00 am ET
FibroGen to Report Third Quarter 2021 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2021 financial results on Tuesday, November 9 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment...
Oct 25, 2021 07:00 am ET
FibroGen Announces Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2021
FibroGen, Inc. (NASDAQ: FGEN), today announced that analyses from the global Phase 3 roxadustat clinical program will be presented at the American Society of Nephrology Kidney Week 2021 taking place virtually November 4 - 7, 2021. A total of 18...
Aug 25, 2021 07:00 am ET
FibroGen Announces Positive Topline Results from Phase 2 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
FibroGen, Inc. (NASDAQ: FGEN) today announced positive topline results from WHITNEY, the Company’s Phase 2 clinical study of roxadustat, a first-in-class oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the...
Aug 20, 2021 08:55 am ET
Thinking about buying stock in Geovax Labs, Marker Therapeutics, Agile Therapeutics, FibroGen, or Pixelworks?
NEW YORK, Aug. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GOVX, MRKR, AGRX, FGEN, and PXLW.
Aug 19, 2021 07:35 pm ET
Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced that the European Commission (EC) has approved EVRENZO™ (roxadustat) for the...
Aug 19, 2021 07:30 pm ET
Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
TOKYO, Aug. 19, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced that the European Commission (EC) has approved EVRENZO™ (roxadustat) for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease (CKD).
Aug 16, 2021 07:00 am ET
FibroGen Announces Retirement of Pat Cotroneo and Appointment of Juan Graham as Chief Financial Officer
FibroGen, Inc. (NASDAQ: FGEN) announced the retirement of Pat Cotroneo, Chief Financial Officer, and the appointment of Juan Graham in that role. Pat will continue as Chief Financial Officer through September 6, 2021, and will remain with FibroGen...
Aug 11, 2021 07:00 am ET
FibroGen Receives Complete Response Letter from the FDA for Roxadustat for Anemia of Chronic Kidney Disease
FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for roxadustat for the treatment of anemia of chronic kidney disease...
Aug 09, 2021 04:01 pm ET
FibroGen Reports Second Quarter 2021 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the second quarter 2021 and provided an update on the Company’s recent developments. “We continue to be energized by the performance of roxadustat in China, where we are seeing...
Jul 29, 2021 07:00 am ET
FibroGen to Report Second Quarter 2021 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2021 financial results on Monday, August 9 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community...
Jul 19, 2021 07:00 am ET
Eluminex Biosciences Exclusively Licenses FibroGen’s Biosynthetic Cornea Technology and Recombinant Collagen III Platform
Eluminex Biosciences (Suzhou) Limited (Eluminex), an ophthalmology-focused biotechnology company headquartered in Suzhou, China with a US-subsidiary office in San Francisco Bay Area, California, announced today that it has exclusively licensed...
Jul 15, 2021 06:26 pm ET
FibroGen Announces Outcome of FDA Advisory Committee Review of Roxadustat for Treatment of Anemia of Chronic Kidney Disease
FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted to recommend not approving roxadustat, an oral hypoxia-inducible factor prolyl...
Jul 12, 2021 07:00 am ET
FibroGen Appoints John Hunter, Ph.D. as Chief Scientific Officer
FibroGen, Inc. (NASDAQ: FGEN) announced the appointment of John Hunter, Ph.D., to the position of Chief Scientific Officer, where he will lead FibroGen’s research efforts, leveraging more than 20 years of global biopharmaceutical leadership and...
Jun 25, 2021 09:15 am ET
Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced the Committee for Medicinal Products for Human Use (CHMP) of the European...
Jun 25, 2021 08:56 am ET
Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
TOKYO, June 25, 2021 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion relating to the use of roxadustat for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease (CKD).1 CKD impacts one in 10 people globally, of whom one in five are affected by anemia.2, 3 Anemia of CKD is associated with
Jun 25, 2021 08:30 am ET
Thinking about buying stock in Pieris Pharmaceuticals, Paysafe, Tonix Pharmaceuticals, FibroGen, or Arbutus Biopharma?
NEW YORK, June 25, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PIRS, PSFE, TNXP, FGEN, and ABUS.
Jun 17, 2021 07:00 am ET
FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease
FibroGen, Inc. (Nasdaq: FGEN) and HiFiBiO Therapeutics, a private, multinational clinical-stage biotherapeutics company with expertise in immune modulation and single cell science announced a partnership covering three HiFiBiO programs. “We are...
Jun 16, 2021 08:00 am ET
Pamrevlumab Included in Pancreatic Cancer Action Network’s Adaptive Clinical Trial Platform
FibroGen, Inc. (NASDAQ: FGEN) announced activation of an experimental arm in the Pancreatic Cancer Action Network's (PanCAN) Precision PromiseSM adaptive trial platform evaluating pamrevlumab [and standard of care] for patients with metastatic...
Jun 14, 2021 07:39 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline – FGEN
Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN) and certain of its officers. The class action, filed in the United States District Court for the Northern...
Jun 11, 2021 09:40 am ET
FGEN FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages FibroGen, Inc. Investors with Losses to Secure Counsel Before Important June 11 Deadline in Securities Class Action – FGEN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of FibroGen, Inc. (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021, inclusive (the “Class Period”), of the important June 11, 2021 lead...
Jun 10, 2021 11:57 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline - FGEN
NEW YORK, June 10, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers.   The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-03212, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired FibroGen securities and/or sold put options from November 8, 2019, through and including April 6, 2021 (the "Class Period"), seeking to re
Jun 10, 2021 09:49 pm ET
FibroGen, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of FibroGen, Inc. (NASDAQ: FGEN) investors that acquired shares between November 8, 2019 and April 6, 2021. Investors have until June 11, 2021 to seek an...
Jun 10, 2021 07:00 pm ET
FIBROGEN 24 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against FibroGen,
NEW ORLEANS, June 10, 2021 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until June 11, 2021 to file lead plaintiff applications in securities class action lawsuits against FibroGen, Inc. (NasdaqGS: FGEN), if they purchased the Company's securities and/or sold put options between October 18, 2017 and April 6, 2021, inclusive (the "Class Period"). These actions are pending in the United States District Court for the Northern District of California.
Jun 10, 2021 11:50 am ET
FINAL DEADLINE TOMORROW: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact
LOS ANGELES, June 10, 2021 /PRNewswire/ -- The Schall Law Firm announced today that they have filed a securities class action lawsuit on behalf of plaintiff Thomas Leonard against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers, which expands the class period. The class action is on behalf of a class consisting of investors who purchased or otherwise acquired FibroGen securities between October 18, 2017 and April 6, 2021, inclusive (the "Class Period"). Plaintiff seeks to recover compensable damages caused by Defendants' violations of the federal secur
Jun 10, 2021 10:00 am ET
Last Few Days to Actively Participate: FibroGen, Inc. (FGEN) Class Action - Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ: FGEN) and certain of its officers, on behalf of shareholders who...
Jun 09, 2021 09:28 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS CAN, CS, FGEN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: FibroGen, Inc. (FGEN)Class Period: 10/18/2017 - 4/6/2021Lead Plaintiff Motion Deadline: June 11,...
Jun 09, 2021 09:00 pm ET
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against FibroGen, Inc. and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors that purchased FibroGen, Inc. (NASDAQ: FGEN) securities and/or sold put options from October 18, 2017 and April 6, 2021, inclusive (the “Class Period”). Investors have until June 11, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Jun 09, 2021 06:59 pm ET
FIBROGEN DEADLINE ALERT: Faruqi & Faruqi LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. (“FibroGen” or the “Company”) (NASDAQ:FGEN) and reminds investors of the June 11, 2021 deadline to seek the role of lead...
Jun 09, 2021 05:21 pm ET
FGEN Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors or June 11, 2021 Deadline in Securities Fraud Class Action Lawsuit
The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against FibroGen, Inc. (NASDAQ: FGEN) (“FibroGen”) on behalf of those who purchased or acquired FibroGen securities and/or sold put options from October 18, 2017 through April 6, 2021, inclusive (the “Class Period”).
Jun 09, 2021 11:30 am ET
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN)
The Law Offices of Frank R. Cruz reminds investors of the upcoming June 11, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired FibroGen Inc. (“FibroGen” or the “Company”) (NASDAQ:
Jun 08, 2021 10:51 pm ET
FIBROGEN 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against FibroGen,
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until June 11, 2021 to file lead plaintiff applications in securities class action lawsuits against FibroGen, Inc. (NasdaqGS: FGEN), if they purchased the Company’s securities and/or sold put options between October 18, 2017 and April 6, 2021, inclusive (the “Class Period”). These actions are pending in the United States District Court for the Northern District of California.
Jun 08, 2021 10:38 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of FGEN, PTON and UI
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. FibroGen, Inc. (FGEN)Class Period: October 18, 2017 and April 6, 2021Lead Plaintiff Motion Deadline: June 11,...
Jun 08, 2021 06:10 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline – FGEN
Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN) and certain of its officers.   The class action, filed in the United States District Court for the Northern...
Jun 08, 2021 01:14 pm ET
Lead Plaintiff Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.
The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against FibroGen, Inc. (NASDAQ: FGEN)...
Jun 08, 2021 11:00 am ET
FGEN Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds FibroGen, Inc. Investors of Class Action and Encourages Investors to Contact the Firm
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ: FGEN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired FibroGen securities between December 20, 2018 and April 6, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site:
Jun 07, 2021 11:03 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS DOX, FGEN, PTON, UI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Amdocs Limited (DOX)Class Period: 12/13/2016 -...
Jun 05, 2021 03:15 pm ET
FGEN BREAKING NEWS: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages FibroGen, Inc. Investors with Losses to Secure Counsel Before Important June 11 Deadline in Securities Class Action – FGEN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of FibroGen, Inc. (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021, inclusive (the “Class Period”), of the important June 11, 2021 lead plaintiff...
Jun 04, 2021 10:00 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS CAN, CS, DOX, FGEN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Amdocs Limited (DOX)Class Period: 12/13/2016 - 3/30/2021Lead Plaintiff Motion Deadline: June 8,...
Jun 04, 2021 01:20 pm ET
FGEN DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds Investors of FibroGen, Inc. of Deadline in Securities Fraud Class Action Lawsuit
The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against FibroGen, Inc. (NASDAQ: FGEN)...
Jun 03, 2021 08:49 pm ET
FibroGen, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of FibroGen, Inc. (NASDAQ: FGEN) investors that acquired shares between November 8, 2019 and April 6, 2021. Investors have until June 11, 2021 to seek an...
Jun 03, 2021 10:14 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline – FGEN
Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN) and certain of its officers.   The class action, filed in the United States District Court for the Northern...
Jun 02, 2021 10:01 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS DOX, FGEN, PTON, UI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Amdocs Limited (DOX)Class Period: 12/13/2016 -...
Jun 01, 2021 10:00 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of DOX, FGEN, PTON and UI
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Amdocs Limited (DOX)Class Period: December 13, 2016 and March 30, 2021Lead Plaintiff Motion Deadline: June 8,...
Jun 01, 2021 11:15 am ET
DEADLINE ALERT for DDD, DOX, SHRMF, and FGEN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
May 31, 2021 10:15 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS CAN, CS, DOX, FGEN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Amdocs Limited (DOX)Class Period: 12/13/2016 - 3/30/2021Lead Plaintiff Motion Deadline: June 8,...
May 31, 2021 05:14 pm ET
FGEN Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of FibroGen, Inc. of Deadline in Securities Fraud Class Action Lawsuit
The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against FibroGen, Inc. (NASDAQ: FGEN)...
May 28, 2021 10:00 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS DOX, FGEN, GOEV, PTON INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Amdocs Limited (DOX)Class Period: 12/13/2016 -...
May 28, 2021 07:06 pm ET
FIBROGEN DEADLINE ALERT: Faruqi & Faruqi LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. (“FibroGen” or the “Company”) (NASDAQ:FGEN) and reminds investors of the June 11, 2021 deadline to seek the role of lead...
May 27, 2021 02:58 pm ET
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages FibroGen, Inc. Investors to Secure Counsel Before Important June 11 Deadline in Securities Class Action – FGEN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of FibroGen, Inc. (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021, inclusive (the “Class Period”), of the important June 11, 2021 lead plaintiff...
May 27, 2021 10:00 am ET
Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.
The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against FibroGen, Inc. (NASDAQ: FGEN)...
May 27, 2021 10:00 am ET
FGEN, CAN & RMO Upcoming Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
May 27, 2021 07:00 am ET
FibroGen to Present at Upcoming Investor Conferences
FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following virtual healthcare conferences: Jefferies Virtual Healthcare Conference on Friday, June 4, 2021 at...
May 26, 2021 10:45 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS CAN, CS, DOX, FGEN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Amdocs Limited (DOX)Class Period: 12/13/2016 - 3/30/2021Lead Plaintiff Motion Deadline: June 8,...
May 26, 2021 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FibroGen, Canaan, Credit Suisse, and Franklin Wireless and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of FibroGen, Inc. (NASDAQ: FGEN), Canaan, Inc. (NASDAQ: CAN), Credit Suisse Group...
May 26, 2021 03:53 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline – FGEN
Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN) and certain of its officers.   The class action, filed in the United States District Court for the Northern...
May 25, 2021 10:00 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of DOX, FGEN, GOEV and PTON
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Canoo Inc. (GOEV, GOEVW)Class Period: August 18, 2020 and March 29, 2021Lead Plaintiff Motion Deadline: June 1,...
May 25, 2021 12:30 pm ET
DEADLINE ALERT for DDD, DOX, SHRMF, FGEN: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
May 25, 2021 10:56 am ET
INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Reminds Investors of Securities Class Action Against FibroGen, Inc. – FGEN and June 11 Deadline
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, announces the filing of a class action lawsuit against FibroGen, Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN) and certain of...
May 25, 2021 08:00 am ET
FibroGen, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of FibroGen, Inc. (NASDAQ: FGEN) investors that acquired shares between November 8, 2019 and April 6, 2021. Investors have until June 11, 2021 to seek an...
May 24, 2021 10:48 pm ET
DOX, FGEN, GOEV, PTON SHAREHOLDERS - ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action lawsuits filed on behalf of Investors, Lead Plaintiff Deadlines Set
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Canoo Inc. (GOEV, GOEVW)Class Period: 8/18/2020 -...
May 24, 2021 12:00 pm ET
DEADLINE ALERT for DDD, DOX, SHRMF, and FGEN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
May 23, 2021 04:09 pm ET
Investor Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. (FGEN)
The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against FibroGen, Inc. (NASDAQ: FGEN) (“FibroGen”)...
May 23, 2021 10:48 am ET
HAGENS BERMAN Reminds FibroGen (FGEN) Investors of Securities Fraud Lawsuit and June 11th Deadline, Encourages Investors with Losses to Contact the Firm
Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. Class Period: Oct. 18, 2017 – Apr. 6, 2021Lead Plaintiff Deadline: June 11, 2021Visit: www.hbsslaw.com/cases/FGEN Contact An Attorney...
May 21, 2021 10:00 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS CAN, CS, DOX, FGEN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Amdocs Limited (DOX)Class Period: 12/13/2016 - 3/30/2021Lead Plaintiff Motion Deadline: June 8,...
May 21, 2021 06:49 pm ET
FIBROGEN DEADLINE ALERT: Faruqi & Faruqi LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. (“FibroGen” or the “Company”) (NASDAQ:FGEN) and reminds investors of the June 11, 2021 deadline to seek the role of lead...
May 20, 2021 09:48 am ET
INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Reminds Investors of Securities Class Action Against FibroGen, Inc. – FGEN and June 11 Deadline
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, announces the filing of a class action lawsuit against FibroGen, Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN) and certain of its officers, alleging violations of federal securities laws. If
May 19, 2021 11:30 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline – FGEN
Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN) and certain of its officers.   The class action, filed in the United States District Court for the Northern...
May 19, 2021 10:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FibroGen, Canaan, Credit Suisse, and Franklin Wireless and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of FibroGen, Inc. (NASDAQ: FGEN), Canaan, Inc. (NASDAQ: CAN), Credit Suisse Group...
May 19, 2021 10:00 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS DOX, FGEN, GOEV, PTON INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Canoo Inc. (GOEV, GOEVW)Class Period: 8/18/2020...
May 19, 2021 02:02 pm ET
Shareholder Alert: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of FibroGen, Inc. of Securities Class Action Lawsuit
The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against FibroGen, Inc. (NASDAQ: FGEN)...
May 19, 2021 10:00 am ET
FGEN, CAN & RMO Class Action Reminders: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
May 18, 2021 10:52 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of DOX, FGEN, GOEV and PTON
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Canoo Inc. (GOEV, GOEVW)Class Period: August 18, 2020 and March 29, 2021Lead Plaintiff Motion Deadline: June 1,...
May 18, 2021 11:48 am ET
HAGENS BERMAN Encourages FibroGen (FGEN) Investors with Losses to Contact the Firm, Securities Fraud Class Action Filed
Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. Class Period: Oct. 18, 2017 – Apr. 6, 2021Lead Plaintiff Deadline: June 11, 2021Visit: www.hbsslaw.com/cases/FGEN Contact An Attorney...
May 18, 2021 11:46 am ET
DEADLINE ALERT for DDD, DOX, SHRMF, FGEN: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
May 17, 2021 10:00 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS CAN, CS, DOX, FGEN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Amdocs Limited (DOX)Class Period: 12/13/2016 - 3/30/2021Lead Plaintiff Motion Deadline: June 8,...
May 17, 2021 11:15 am ET
DEADLINE ALERT for DDD, DOX, SHRMF, and FGEN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
May 15, 2021 03:18 pm ET
Lead Plaintiff Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. - Expanded Class Period
The law firm of Kessler Topaz Meltzer & Check, LLP announces that securities fraud class action lawsuits have been filed in the United States District Court for the Northern District of California against FibroGen, Inc. (NASDAQ: FGEN) (“FibroGen”)...
May 14, 2021 10:50 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline – FGEN
Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN) and certain of its officers.   The class action, filed in the United States District Court for the Northern...
May 14, 2021 10:50 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS DOX, FGEN, GOEV, VRM INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Vroom, Inc. (VRM)Class Period: 6/9/2020 -...
May 14, 2021 12:00 pm ET
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN)
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 11, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired FibroGen Inc. (“FibroGen” or the...
May 13, 2021 10:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FibroGen, Canaan, Credit Suisse, and Franklin Wireless and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of FibroGen, Inc. (NASDAQ: FGEN), Canaan, Inc. (NASDAQ: CAN), Credit Suisse Group...
May 13, 2021 10:16 am ET
FGEN INVESTORS ACT NOW: Contact HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, to Recover Losses Due to Alleged Securities Fraud
Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. Class Period:Oct. 18, 2017 – Apr. 6, 2021Lead Plaintiff Deadline:June 11, 2021Visit:www.hbsslaw.com/cases/FGEN  Contact An Attorney...
May 12, 2021 09:46 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS CAN, CS, DOX, FGEN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Amdocs Limited (DOX)Class Period: 12/13/2016 - 3/30/2021Lead Plaintiff Motion Deadline: June 8,...
May 12, 2021 05:54 pm ET
ROSEN, SKILLED INVESTOR COUNSEL, Encourages FibroGen, Inc. Investors to Secure Counsel Before Important June 11 Deadline in Securities Class Action – FGEN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of FibroGen, Inc. (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021, inclusive (the “Class Period”), of the important June 11, 2021 lead plaintiff...
May 12, 2021 12:05 pm ET
DEADLINE ALERT for DDD, DOX, SHRMF, and FGEN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
May 11, 2021 10:30 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of DOX, FGEN and GOEV
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Canoo Inc. (GOEV, GOEVW)Class Period: August 18, 2020 and March 29, 2021Lead Plaintiff Motion Deadline: June 1,...
May 11, 2021 06:51 pm ET
FGEN CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds FibroGen, Inc. Shareholders of Securities Fraud Class Action Lawsuit
The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against FibroGen, Inc. (NASDAQ: FGEN)...
May 11, 2021 06:29 pm ET
FibroGen, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of FibroGen, Inc. (NASDAQ: FGEN) investors that acquired shares between November 8, 2019 and April 6, 2021. Investors have until June 11, 2021 to seek an...
May 11, 2021 08:40 am ET
SHAREHOLDER ACTION ALERT: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc.
The Schall Law Firm announced today that they have filed a securities class action lawsuit on behalf of plaintiff Thomas Leonard against FibroGen, Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN) and certain of its officers, which expands the class period. The class action is on behalf of a class consisting of investors who purchased or otherwise acquired FibroGen securities between October 18, 2017 and April 6, 2021, inclusive (the “Class Period”). Plaintiff seeks to recover compensable damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Secti
May 10, 2021 11:15 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS DOX, FGEN, GOEV INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Canoo Inc. (GOEV, GOEVW)Class Period: 8/18/2020 -...
May 10, 2021 04:01 pm ET
FibroGen Reports First Quarter 2021 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2021 and provided an update on the Company’s recent developments. “We are pleased at the continued adoption and growth of roxadustat in China,” said Enrique...
May 10, 2021 12:18 pm ET
The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc.
The Schall Law Firm and Roche Freedman LLP announced today that they have filed a securities class action lawsuit on behalf of plaintiff Thomas Leonard against FibroGen, Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN) and certain of its officers, which expands the class period. The class action is on behalf of a class consisting of investors who purchased or otherwise acquired FibroGen securities between October 18, 2017 and April 6, 2021, inclusive (the “Class Period”). Plaintiff seeks to recover compensable damages caused by Defendants' violations of the federal securities laws and to purs
May 08, 2021 01:15 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts FibroGen (FGEN) Investors to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors Should Secure Counsel
Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. Class Period: Oct. 18, 2017 – Apr. 6, 2021Lead Plaintiff Deadline: June 11, 2021Visit: www.hbsslaw.com/cases/FGEN Contact An...
May 07, 2021 10:40 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS CAN, CS, DOX, FGEN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Amdocs Limited (DOX)Class Period: 12/13/2016 - 3/30/2021Lead Plaintiff Motion Deadline: June 8,...
May 07, 2021 07:05 pm ET
Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. – Expanded Class Period
The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against FibroGen, Inc. (NASDAQ: FGEN)...
May 07, 2021 12:00 pm ET
DEADLINE ALERT for DDD, DOX, SHRMF, FGEN: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
May 05, 2021 11:01 pm ET
SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS DOX, FGEN, GOEV, WKHS INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Workhorse Group, Inc. (WKHS)Class Period: 7/7/2020...
May 05, 2021 10:12 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FibroGen, Canaan, Credit Suisse, and Franklin Wireless and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of FibroGen, Inc. (NASDAQ: FGEN), Canaan, Inc. (NASDAQ: CAN), Credit Suisse Group...
May 05, 2021 11:15 am ET
DEADLINE ALERT for DDD, DOX, SHRMF, and FGEN: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
May 04, 2021 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of DOX, FGEN, GOEV and WKHS
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Workhorse Group, Inc. (WKHS)Class Period: July 7, 2020 and February 23, 2021Lead Plaintiff Motion Deadline: May...
May 04, 2021 09:11 pm ET
FibroGen, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of FibroGen, Inc. (NASDAQ: FGEN) investors that acquired shares between November 8, 2019 and April 6, 2021. Investors have until June 11, 2021 to seek an...
May 04, 2021 10:04 am ET
FGEN SHAREHOLDER FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Fibrogen Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
May 03, 2021 11:03 pm ET
SHAREHOLDER ALERT: CLAIMSFILER REMINDS CAN, CS, DOX, FGEN INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Amdocs Limited (DOX)Class Period: 12/13/2016 - 3/30/2021Lead Plaintiff Motion Deadline: June 8,...
May 03, 2021 02:00 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts FibroGen (FGEN) Investors to Securities Fraud Lawsuit and Application Deadline, Advises Investors with Losses to Contact Its Attorneys Now
Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. Class Period: Nov. 8, 2019 – Apr. 6, 2021Lead Plaintiff Deadline: June 11, 2021Visit: www.hbsslaw.com/cases/FGEN Contact An Attorney...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.